{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:18:55Z","timestamp":1764645535644,"version":"3.41.2"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>No validated assessment tools are available to evaluate patient-reported outcomes specifically related to submental fat (SMF).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To develop and validate scales measuring the severity (Patient-Reported SMF Rating Scale [PR-SMFRS]) and psychological impact (Patient-Reported SMF Impact Scale [PR-SMFIS]) of SMF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>A literature review, content validation interviews (concept elicitation [<jats:italic toggle=\"yes\">n<\/jats:italic> = 29] and cognitive debriefing [<jats:italic toggle=\"yes\">n<\/jats:italic> = 15]) in adults with SMF, and expert interviews (<jats:italic toggle=\"yes\">n<\/jats:italic> = 3) were conducted to develop the PR-SMFRS and PR-SMFIS. Psychometric validity (acceptability, reliability, and validity) for the PR-SMFRS and PR-SMFIS was assessed using data from 1 phase 2 and 5 phase 3 ATX-101 studies in patients with excess SMF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The PR-SMFRS was constructed as a single-item, 5-point rating of the SMF amount\/size. The PR-SMFIS was constructed as a 6-item scale, with an 11-point numeric rating for each item. Both scales demonstrated acceptable psychometric properties (test\u2013retest reliability and internal consistency). The anchor-based minimally important difference analysis suggests a 1-point improvement on the PR-SMFRS (scale of 0\u20124) and a 3-point improvement on the PR-SMFIS (scale of 0\u201210) represent clinically meaningful change.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The PR-SMFRS and PR-SMFIS are reliable, valid instruments for assessing the severity and psychosocial impact, respectively, of SMF and detecting clinically meaningful change with intervention.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002908","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T18:11:47Z","timestamp":1607623907000},"page":"522-525","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Development and Validation of the Patient-Reported Submental Fat Rating Scale and the Patient-Reported Submental Fat Impact Scale"],"prefix":"10.1097","volume":"47","author":[{"given":"Mary","family":"Lupo","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Dover","sequence":"additional","affiliation":[{"name":"SkinCare Physicians, Chestnut Hill, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Baradaran","sequence":"additional","affiliation":[{"name":"Health Economics & Outcomes Research, Allergan Aesthetics, an AbbVie Company, Irvine, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Patel","sequence":"additional","affiliation":[{"name":"Health Economics & Outcomes Research, Allergan Aesthetics, an AbbVie Company, Irvine, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"Drinkwater","sequence":"additional","affiliation":[{"name":"Peloton Advantage, an OPEN Health company, Parsippany, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"R1-20250731","first-page":"27","article-title":"Perceptions and practices in submental fat treatment: a survey of physicians and patients","volume":"11","author":"Schlessinger","year":"2013","journal-title":"Skinmed"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/DSS.0000000000001648","article-title":"Personal (self) perceptions of submental fat among adults in the United States","volume":"45","author":"Baumann","year":"2019","journal-title":"Dermatol Surg"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/jdv.12377","article-title":"Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study","volume":"28","author":"Ascher","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjd.12695","article-title":"Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study","volume":"170","author":"Rzany","year":"2014","journal-title":"Br J Dermatol"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/DSS.0000000000000578","article-title":"REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction","volume":"42","author":"Jones","year":"2016","journal-title":"Dermatol Surg"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaad.2016.04.028","article-title":"ATX-101 for reduction of submental fat: a phase III randomized controlled trial","volume":"75","author":"Humphrey","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R12-20250731","first-page":"870","article-title":"ATX-101 (deoxycholic acid injection) for reduction of submental fat: results from a 12-month open-label study","volume":"18","author":"Beer","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0149-2918(96)80054-3","article-title":"Evaluating quality-of-life and health status instruments: development of scientific review criteria","volume":"18","author":"Lohr","year":"1996","journal-title":"Clin Ther"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.314.7080.572","article-title":"Cronbach's alpha","volume":"314","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00266-014-0364-9","article-title":"Results from a pooled analysis of two European, randomized, placebo-controlled, phase 3 studies of ATX-101 for the pharmacologic reduction of excess submental fat","volume":"38","author":"McDiarmid","year":"2014","journal-title":"Aesthet Plast Surg"},{"key":"R21-20250731","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"R22-20250731","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0030-1262313","article-title":"Measuring patient-reported outcomes in facial aesthetic patients: development of the FACE-Q","volume":"26","author":"Klassen","year":"2010","journal-title":"Facial Plast Surg"},{"key":"R23-20250731","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.det.2017.09.007","article-title":"Noninvasive body contouring: a male perspective","volume":"36","author":"Wat","year":"2018","journal-title":"Dermatol Clin"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:13:04Z","timestamp":1753999984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002908","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"type":"print","value":"1076-0512"},{"type":"electronic","value":"1524-4725"}],"subject":[],"published":{"date-parts":[[2020,12,2]]}}}